Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity.

Sustmann C, Dickopf S, Regula JT, Kettenberger H, Mølhøj M, Gassner C, Weininger D, Fenn S, Manigold T, Kling L, Künkele KP, Schwaiger M, Bossenmaier B, Griese JJ, Hopfner KP, Graff-Meyer A, Stahlberg H, Ringler P, Lauer ME, Brinkmann U, Schaefer W, Klein C.

MAbs. 2019 Nov-Dec;11(8):1402-1414. doi: 10.1080/19420862.2019.1661736. Epub 2019 Sep 17.

2.

Acquired Resistance to Antibody-Drug Conjugates.

Collins DM, Bossenmaier B, Kollmorgen G, Niederfellner G.

Cancers (Basel). 2019 Mar 20;11(3). pii: E394. doi: 10.3390/cancers11030394. Review.

3.

Translation and evaluation of a pre-clinical 5-protein response prediction signature in a breast cancer phase Ib clinical trial.

Ducret A, James I, Wilson S, Feilke M, Tebbe A, Dybowski N, Elschenbroich S, Klammer M, Blackler A, Liao WL, Tian Y, Friess T, Bossenmaier B, Dietmann G, Schaab C, Hembrough T, Ceppi M.

PLoS One. 2019 Mar 21;14(3):e0213892. doi: 10.1371/journal.pone.0213892. eCollection 2019.

4.

Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.

Leshem Y, O'Brien J, Liu X, Bera TK, Terabe M, Berzofsky JA, Bossenmaier B, Niederfellner G, Tai CH, Reiter Y, Pastan I.

Cancer Immunol Res. 2017 Aug;5(8):685-694. doi: 10.1158/2326-6066.CIR-16-0330. Epub 2017 Jul 3.

5.

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.

Meulendijks D, Jacob W, Voest EE, Mau-Sorensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langenberg MHG, De Jonge MJ, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Vega-Harring S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN.

Clin Cancer Res. 2017 Sep 15;23(18):5406-5415. doi: 10.1158/1078-0432.CCR-17-0812. Epub 2017 Jun 9.

6.

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.

Collins D, Jacob W, Cejalvo JM, Ceppi M, James I, Hasmann M, Crown J, Cervantes A, Weisser M, Bossenmaier B.

PLoS One. 2017 May 11;12(5):e0177331. doi: 10.1371/journal.pone.0177331. eCollection 2017.

7.

Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.

Bauss F, Lechmann M, Krippendorff BF, Staack R, Herting F, Festag M, Imhof-Jung S, Hesse F, Pompiati M, Kollmorgen G, da Silva Mateus Seidl R, Bossenmaier B, Lau W, Schantz C, Stracke JO, Brinkmann U, Onda M, Pastan I, Bosslet K, Niederfellner G.

Mol Oncol. 2016 Oct;10(8):1317-29. doi: 10.1016/j.molonc.2016.07.003. Epub 2016 Jul 14.

8.

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.

Meulendijks D, Jacob W, Martinez-Garcia M, Taus A, Lolkema MP, Voest EE, Langenberg MH, Fleitas Kanonnikoff T, Cervantes A, De Jonge MJ, Sleijfer S, Soerensen MM, Thomas M, Ceppi M, Meneses-Lorente G, James I, Adessi C, Michielin F, Abiraj K, Bossenmaier B, Schellens JH, Weisser M, Lassen UN.

Clin Cancer Res. 2016 Feb 15;22(4):877-85. doi: 10.1158/1078-0432.CCR-15-1683. Epub 2015 Oct 13.

9.

Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody.

Meneses-Lorente G, Friess T, Kolm I, Hölzlwimmer G, Bader S, Meille C, Thomas M, Bossenmaier B.

Cancer Chemother Pharmacol. 2015 Apr;75(4):837-50. doi: 10.1007/s00280-015-2697-8. Epub 2015 Feb 22.

10.

Deciphering the stepwise binding mode of HRG1β to HER3 by surface plasmon resonance and interaction map.

Peess C, von Proff L, Goller S, Andersson K, Gerg M, Malmqvist M, Bossenmaier B, Schräml M.

PLoS One. 2015 Feb 6;10(2):e0116870. doi: 10.1371/journal.pone.0116870. eCollection 2015.

11.

ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116.

Terwisscha van Scheltinga AG, Lub-de Hooge MN, Abiraj K, Schröder CP, Pot L, Bossenmaier B, Thomas M, Hölzlwimmer G, Friess T, Kosterink JG, de Vries EG.

MAbs. 2014 Jul-Aug;6(4):1051-8. doi: 10.4161/mabs.29097. Epub 2014 May 7.

12.

Development of bispecific molecules for the in situ detection of protein-protein interactions and protein phosphorylation.

van Dieck J, Schmid V, Heindl D, Dziadek S, Schraeml M, Gerg M, Massoner P, Engel AM, Tiefenthaler G, Vural S, Stritt S, Tetzlaff F, Soukupova M, Kopetzki E, Bossenmaier B, Thomas M, Klein C, Mertens A, Heller A, Tacke M.

Chem Biol. 2014 Mar 20;21(3):357-68. doi: 10.1016/j.chembiol.2013.12.018. Epub 2014 Feb 13.

13.

Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy.

Kollmorgen G, Niederfellner G, Lifke A, Spohn GJ, Rieder N, Harring SV, Bauss F, Burtscher H, Lammers R, Bossenmaier B.

Mol Oncol. 2013 Dec;7(6):1142-51. doi: 10.1016/j.molonc.2013.08.009. Epub 2013 Sep 3.

14.

RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation.

Mirschberger C, Schiller CB, Schräml M, Dimoudis N, Friess T, Gerdes CA, Reiff U, Lifke V, Hoelzlwimmer G, Kolm I, Hopfner KP, Niederfellner G, Bossenmaier B.

Cancer Res. 2013 Aug 15;73(16):5183-94. doi: 10.1158/0008-5472.CAN-13-0099. Epub 2013 Jun 18.

15.

Structural requirements for cub domain containing protein 1 (CDCP1) and Src dependent cell transformation.

Kollmorgen G, Bossenmaier B, Niederfellner G, Häring HU, Lammers R.

PLoS One. 2012;7(12):e53050. doi: 10.1371/journal.pone.0053050. Epub 2012 Dec 31.

16.

GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.

Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, Bossenmaier B, Mueller HJ, Umaña P.

Clin Cancer Res. 2013 Mar 1;19(5):1126-38. doi: 10.1158/1078-0432.CCR-12-0989. Epub 2012 Dec 3.

17.

Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing.

Metz S, Panke C, Haas AK, Schanzer J, Lau W, Croasdale R, Hoffmann E, Schneider B, Auer J, Gassner C, Bossenmaier B, Umana P, Sustmann C, Brinkmann U.

Protein Eng Des Sel. 2012 Oct;25(10):571-80. Epub 2012 Sep 13.

18.

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.

Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M.

Cancer Res. 2009 Dec 15;69(24):9330-6. doi: 10.1158/0008-5472.CAN-08-4597.

19.

The 1.1 A resolution crystal structure of the p130cas SH3 domain and ramifications for ligand selectivity.

Wisniewska M, Bossenmaier B, Georges G, Hesse F, Dangl M, Künkele KP, Ioannidis I, Huber R, Engh RA.

J Mol Biol. 2005 Apr 15;347(5):1005-14.

PMID:
15784259
20.

Serine residues 1177/78/82 of the insulin receptor are required for substrate phosphorylation but not autophosphorylation.

Bossenmaier B, Strack V, Stoyanov B, Krützfeldt J, Beck A, Lehmann R, Kellerer M, Klein H, Ullrich A, Lammers R, Häring HU.

Diabetes. 2000 Jun;49(6):889-95.

PMID:
10866039
21.

Serine residues 994 and 1023/25 are important for insulin receptor kinase inhibition by protein kinase C isoforms beta2 and theta.

Strack V, Hennige AM, Krützfeldt J, Bossenmaier B, Klein HH, Kellerer M, Lammers R, Häring HU.

Diabetologia. 2000 Apr;43(4):443-9.

PMID:
10819237
22.
23.

The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin.

Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Häring HU.

Horm Metab Res. 1998 Mar;30(3):123-9.

PMID:
9566852
24.

A 973 valine to methionine mutation of the human insulin receptor: interaction with insulin-receptor substrate-1 and Shc in HEK 293 cells.

Strack V, Bossenmaier B, Stoyanov B, Mushack J, Häring HU.

Diabetologia. 1997 Oct;40(10):1135-40.

PMID:
9349593
25.

Impact of mutations at different serine residues on the tyrosine kinase activity of the insulin receptor.

Strack V, Stoyanov B, Bossenmaier B, Mosthaf L, Kellerer M, Häring HU.

Biochem Biophys Res Commun. 1997 Oct 9;239(1):235-9.

PMID:
9345301
26.

Protein kinase C isoforms beta 1 and beta 2 inhibit the tyrosine kinase activity of the insulin receptor.

Bossenmaier B, Mosthaf L, Mischak H, Ullrich A, Häring HU.

Diabetologia. 1997 Jul;40(7):863-6.

PMID:
9243110
27.
28.

Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling.

Kroder G, Bossenmaier B, Kellerer M, Capp E, Stoyanov B, Mühlhöfer A, Berti L, Horikoshi H, Ullrich A, Häring H.

J Clin Invest. 1996 Mar 15;97(6):1471-7.

29.

Modulation of insulin receptor signaling. Potential mechanisms of a cross talk between bradykinin and the insulin receptor.

Häring HU, Tippmer S, Kellerer M, Mosthaf L, Kroder G, Bossenmaier B, Berti L.

Diabetes. 1996 Jan;45 Suppl 1:S115-9. Review.

PMID:
8529791
30.

Acute hyperglycemia provides an insulin-independent inducer for GLUT4 translocation in C2C12 myotubes and rat skeletal muscle.

Galante P, Mosthaf L, Kellerer M, Berti L, Tippmer S, Bossenmaier B, Fujiwara T, Okuno A, Horikoshi H, Häring HU.

Diabetes. 1995 Jun;44(6):646-51.

PMID:
7789629
31.

C-terminus or juxtamembrane deletions in the insulin receptor do not affect the glucose-dependent inhibition of the tyrosine kinase activity.

Mosthaf L, Berti L, Kellerer M, Mushack J, Seffer E, Bossenmaier B, Coghlan M, Siddle K, Ullrich A, Häring HU.

Eur J Biochem. 1995 Feb 1;227(3):787-91.

32.

Differential activities of protein tyrosine phosphatases in intact cells.

Lammers R, Bossenmaier B, Cool DE, Tonks NK, Schlessinger J, Fischer EH, Ullrich A.

J Biol Chem. 1993 Oct 25;268(30):22456-62.

33.

Modulation of p145c-kit function in cells of patients with acute myeloblastic leukemia.

Bühring HJ, Herbst R, Kostka G, Bossenmaier B, Bartke I, Kropshofer H, Kalbacher H, Busch FW, Müller CA, Schlessinger J, et al.

Cancer Res. 1993 Sep 15;53(18):4424-31.

Supplemental Content

Loading ...
Support Center